Daiichi Sankyo Company, Limited DSNKY
Set alert
18.19 USD +0.78 +4.48%
As of Nov 2, 3:59 PM ET
18.10 Day range 18.28
14.98 52-week range 24.77
- YTD
- -14.36%
- 1 year
- -23.67%
- Open
- 18.28
- Prev close
- 17.41
- Mkt cap
- 33.10B
- Vol
- 49.19K
- Avg vol
- 112.58K
- EPS
- 0.89
- P/E
- 20.44
More statistics
- Low
- 18.10
- High
- 18.28
- Earnings
- Oct 30, 2026
2Y chart
Events in this range
- Mar 31, 2025Dividend: 0.20683
- Jul 31, 2025Earnings: 0.3059; estimate 0.2337; surprise 30.89%
- Sep 30, 2025Dividend: 0.24955
- Oct 31, 2025Earnings: 0.1592; estimate 0.2986; surprise -46.68%
- Jan 29, 2026Earnings: 0.3033; estimate 0.2504; surprise 21.13%
- Mar 30, 2026Dividend: 0.24439
- Mar 31, 2026Dividend: 0.24144
- May 11, 2026Earnings: 0.1465; estimate 0.3317; surprise -55.83%
- Jul 31, 2026Earnings: 0.24; estimate 0.2543; surprise -5.62%
- Sep 29, 2026Dividend: 0.31492
- Sep 30, 2026Dividend: 0.3178
- Oct 30, 2026Earnings: —; estimate 0.2362; surprise —%
Signals (101)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2026 | 13 hours ago |
| SMA: Bullish | Nov 2, 2026 | 13 hours ago |
| MACD: Buy Signal | Nov 2, 2026 | 13 hours ago |
| MACD: Sell Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 27, 2026 | 6 days ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Newest 20 of 101.
Next earnings
Oct 30, 2026
Expected Oct 30, 2026. Consensus EPS estimate 0.2362.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.2362 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.2543 | 0.24 | -0.01 | -5.62% |
| May 11, 2026 | Mar 31, 2026 | 0.3317 | 0.1465 | -0.19 | -55.83% |
| Jan 29, 2026 | Dec 31, 2025 | 0.2504 | 0.3033 | +0.05 | +21.13% |
| Oct 31, 2025 | Sep 30, 2025 | 0.2986 | 0.1592 | -0.14 | -46.68% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2337 | 0.3059 | +0.07 | +30.89% |
News
- Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
- Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
- Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union
- Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
- Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
- COLL vs. DSNKY: Which Stock Is the Better Value Option?
- Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
- AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
- AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
- Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
Your note
Sign in to keep a note on DSNKY — it syncs with the Stock Master app.